Phase 3 N=62 Comparision of Different Dose of Neostigmine at Advanced Decurarization
Anesthesia
Primary: Mesure of the Train-of-four (TOF) — 3.8; 4.5; 11.5; 19 minute
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 Effect of Neuromuscular Blockade and Reversal on Breathing
Respiratory Insufficiency
Primary: Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response) — 0.66; 0.43; 0.54; 0.34 L/min/% desaturation
N/A N=81 Optimal Dose of Combination of Rocuronium and Cisatracurium
Chronic Otitis Media · Anesthesia
Primary: Onset of Neuromuscular Blocking Agents(NMBAs) — 212.8; 230.1; 399.3 Second
Phase 4 N=80 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients
Pre-eclampsia Aggravated
Primary: TOF 0.9 Achieving Time — 1.6; 2.1 minutes
Phase 4 N=46 Sugammadex as Rescue Therapy
Neuromuscular Blockade
Primary: The Time Taken to Achieve a TOF Ratio of 0.9 After Administration Sugammadex — 3.13; 2.56; 2.33; 5.00 minutes
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Phase 4 N=19 Fade Upon TOF Stimulation Induced by Succinylcholine
Muscle Relaxants
Primary: Fade on Train of Four Stimulation — 0.85; 0.64; 0.66; 0.68 Ratio
N/A N=250 Evaluation of the Tof Cuff for Perioperative Neuromuscular Transmission
Neuromuscular Blockade
Primary: Depth of Neuromuscular Block During Moderate Neuromuscular Blockade (Outcome Measure/Row Title Train of Four Ratio) and During Deep Neuromuscular Blockade (Outcome…
Phase 4 N=60 Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex
Underdosing of Other General Anesthetics
Primary: Reversal Time of Rocuronium — 124.9; 171.1 seconds
Phase 3 N=91 Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
Neuromuscular Blockade
Primary: Time From Start of Administration of 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.9 Measured by a TOF-Watch® SX — 1.5 Minutes
N/A N=50 TOF Monitoring Using the TetraGraph in Patients Less Than 1 Year of Age
Surgery
Primary: TOFr (%) — 99; 95 percent
Phase 4 N=189 Best Management of Muscle Relaxation- Objective Monitoring
Residual Paralysis, Post Anesthesia
Primary: Incidence of Postoperative Residual Neuromuscular Blockade at Time of Extubation — 0 Participants
Phase 4 N=81 Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block
Airway Reflexes, Protective · Recovery After Neuromuscular Block · Anesthetic Recovery
Primary: Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis. — 16; 25; 10; 6 participants — p=0.11
Phase 2 N=100 A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)
Anesthesia, General
Primary: Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 82.08; 3.95; 2.48; 2.17 Minutes
Phase 4 N=302 Residual Curarization and Its Incidence at Tracheal Extubation (P08194)
Observation of Neuromuscular Block
Primary: Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation — 56 percentage of participants